|
ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP), based in Melbourne, Australia and Menlo Park, Ca, USA, today announced its accelerated clinical development plan for its lead anti-cancer therapeutic, Ceflatonin(R) (homoharringtonine, HHT). The initiation of the first of two registration-directed Phase 2/3 trials is scheduled for the third quarter of 2005. The first trial will target chronic myeloid leukemia (CML) accelerated phase patients who are resistant to high-dose Gleevec(R). New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML YAHOO! GROUPS LINKS
|
